• 1
    Callander NS, Roodman GD 2001 Myeloma bone disease. Sem Hematol 38: 276285.
  • 2
    Mariette X, Khalifa P, Ravaud P, Frija J, Laval-Jeantet M, Chastang C, Brouet JC, Fermand JP 1992 Bone densitometry in patients with multiple myeloma. Am J Med 93: 595598.
  • 3
    Holmes JA, Evans WD, Cole RJ, Ramsahoye B, Whittaker JA 1994 Dual energy X-ray absorptiometry measurements of bone mineral density in myeloma. Eur J Haematol 53: 309311.
  • 4
    Roux C, Ravaud P, Cohen-Solal M, de Vernejoul MC, Guillemant S, Cherruau B, Delmas P, Dougados M, Amor B 1994 Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 15: 4149.
  • 5
    Mariette X, Bergot C, Ravaud P, Roux C, Laval-Jeantet M, Brouet J-C, Fermand J-P 1995 Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. Cancer 76: 15591563.
  • 6
    Diamond T, Levy S, Day P, Barbagallo S, Manoharan A, Kwan YK 1997 Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: Effects of glucocorticoid therapy and disease activity. Br J Haematol 97: 641648.
  • 7
    Dhodapkar MV, Weinstein R, Tricot G, Jagannath S, Parfitt AM, Manolagas SC, Barlogie B 1998 Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leuk Lymphoma 32: 121127.
  • 8
    Diamond T, Levy S, Smith A, Day P, Manoharan A 2001 Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Intern Med J 31: 272278.
  • 9
    Ingeberg S, Deding A, Jensen MK 1982 Bone mineral content in myelomatosis. Acta Med Scand 211: 1921.
  • 10
    Abildgaard N, Brixen K, Kristensen JE, Vejlgaard T, Charles P, Nielsen JL 1996 Assessment of bone involvement in patients with multiple myeloma using bone densitometry. Eur J Haematol 57: 370376.
  • 11
    Laroche M, Pouillès JM, Dromer C, Attal M, Ribot C 1996 Dual-energy x-ray absorptiometry in patients with multiple myeloma and benign gammopathies. Clin Exp Rheumatol 14: 108.
  • 12
    Pfeilschifter J, Diel IJ 2000 Osteoporosis due to cancer treatment: Pathogenesis and management. J Clin Oncol 18: 15701593.
  • 13
    Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR 2003 Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78: 2133.
  • 14
    Cummings SR, Melton LJ 2002 Epidemiology and outcomes of osteoporotic fractures. Lancet 359: 17611767.
  • 15
    Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I 1992 Randomised, placebo-controlled multicenter trial of clodronate in multiple myeloma. Lancet 340: 10491052.
  • 16
    American Cancer Society 2003 Cancer Facts and Figures 2003. American Cancer Society, Atlanta, GA, USA.
  • 17
    Melton LJ III 1996 History of the Rochester Epidemiology Project. Mayo Clin Proc 71: 266274.
  • 18
    Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 2004 Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over six decades. Cancer 101: 26672674.
  • 19
    Melton LJ III 1997 The threat to medical-records research. N Engl J Med 337: 14661470.
  • 20
    Durie BGM, Salmon SE 1975 A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36: 842854.
  • 21
    Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ III 1992 Incidence of clinically diagnosed vertebral fractures: A population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 7: 221227.
  • 22
    Garraway WM, Stauffer RN, Kurland LT, O'Fallon WM 1979 Limb fractures in a defined population. I. Frequency and distribution. Mayo Clin Proc 54: 701707.
  • 23
    Melton LJ III, Sampson JM, Morrey BF, Ilstrup DM 1981 Epidemiologic features of pelvic fractures. Clin Orthop 155: 4347.
  • 24
    Rose SH, Melton LJ III, Morrey BF, Ilstrup DM, Riggs BL 1982 Epidemiologic features of humeral fractures. Clin Orthop 168: 2430.
  • 25
    Arneson TJ, Melton LJ III, Lewallen DG, O'Fallon WM 1988 Epidemiology of diaphyseal and distal femoral fractures in Rochester, Minnesota, 1965–1984. Clin Orthop 234: 188194.
  • 26
    Melton LJ III, Atkinson EJ, Madhok R 1996 Downturn in hip fracture incidence. Public Health Rep 111: 146150.
  • 27
    Melton LJ III, Amadio PC, Crowson CS, O'Fallon WM 1998 Long-term trends in the incidence of distal forearm fractures. Osteoporos Int 8: 341348.
  • 28
    Melton LJ III, Crowson CS, O'Fallon WM 1999 Fracture incidence in Olmsted County, Minnesota: Comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9: 2937.
  • 29
    Cox DR 1953 Some simple approximate tests for Poisson variates. Biometrika 40: 354360.
  • 30
    Kaplan EL, Meier P 1958 Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457481.
  • 31
    Gooley TA, Leisenring W, Crowley J, Storer BE 1999 Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18: 695706.
  • 32
    Kalbfleisch JD, Prentice RL 1980 The Statistical Analysis of Failure Time Data. John Wiley and Sons, New York, NY, USA.
  • 33
    Therneau TM, Grambsch PM 2000 Modeling Survival Data: Extending the Cox Model. Springer-Verlag, New York, NY, USA.
  • 34
    Melton LJ III, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA 2004 Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 19: 2530.
  • 35
    Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ III 2002 A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346: 564569.
  • 36
    Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS 2002 American Society of Clinical Oncology Clinical Practice Guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20: 37193736.
  • 37
    Watts NB 2001 Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 27: 197214.
  • 38
    van Staa TP, Leufkens HGM, Cooper C 2002 The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporos Int 13: 777787.
  • 39
    Clines GA, Guise TA 2003 Hypercalcemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction. In: FavusMJ (ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed. American Society for Bone and Mineral Research, Washington, DC, USA, pp. 251256.
  • 40
    Riggs BL, Khosla S, Melton LJ III 1998 A unitary model for involutional osteoporosis: Estrogen deficiency causes both Type I and Type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13: 763773.
  • 41
    Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M 2000 Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 15: 721739.
  • 42
    Stein E, Shane E 2003 Secondary osteoporosis. Endocrinol Metab Clin North Am 32: 115134.
  • 43
    Greenspan SL, Greenspan FS 1999 The effect of thyroid hormone on skeletal integrity. Ann Intern Med 130: 750758.
  • 44
    Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HAP 2004 Use of statins and fracture: Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164: 146152.